AU9435098A - Tuberculosis vaccine - Google Patents

Tuberculosis vaccine

Info

Publication number
AU9435098A
AU9435098A AU94350/98A AU9435098A AU9435098A AU 9435098 A AU9435098 A AU 9435098A AU 94350/98 A AU94350/98 A AU 94350/98A AU 9435098 A AU9435098 A AU 9435098A AU 9435098 A AU9435098 A AU 9435098A
Authority
AU
Australia
Prior art keywords
nucleic acid
acid molecules
present
tuberculosis vaccine
novel recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU94350/98A
Other languages
English (en)
Inventor
Jurgen Hess
Stefan H. E. Kaufmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of AU9435098A publication Critical patent/AU9435098A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU94350/98A 1997-08-22 1998-08-12 Tuberculosis vaccine Abandoned AU9435098A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97114614A EP0902086A1 (en) 1997-08-22 1997-08-22 Tuberculosis vaccine
EP97114614 1997-08-22
PCT/EP1998/005109 WO1999010496A1 (en) 1997-08-22 1998-08-12 Tuberculosis vaccine

Publications (1)

Publication Number Publication Date
AU9435098A true AU9435098A (en) 1999-03-16

Family

ID=8227261

Family Applications (1)

Application Number Title Priority Date Filing Date
AU94350/98A Abandoned AU9435098A (en) 1997-08-22 1998-08-12 Tuberculosis vaccine

Country Status (13)

Country Link
US (1) US6673353B1 (https=)
EP (2) EP0902086A1 (https=)
JP (1) JP4255209B2 (https=)
AT (1) ATE347599T1 (https=)
AU (1) AU9435098A (https=)
CA (1) CA2301879C (https=)
CY (1) CY1106350T1 (https=)
DE (1) DE69836588T2 (https=)
DK (1) DK1007686T3 (https=)
ES (1) ES2274580T3 (https=)
PT (1) PT1007686E (https=)
SI (1) SI1007686T1 (https=)
WO (1) WO1999010496A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072329A1 (en) 2000-03-29 2001-10-04 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
ID29858A (id) 1998-11-04 2001-10-18 Isis Innovation Uji diagnostik tuberkulosis
GB0006693D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Vaccine
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
PT1618128E (pt) * 2003-04-23 2010-10-13 Max Planck Gesellschaft Vacina de tuberculose com eficácia melhorada
EP1649869A1 (en) 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
CN101198358B (zh) * 2004-12-01 2013-06-26 Aeras全球Tb疫苗基金会 具有增强的逃出内体能力的重组bcg菌株
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
DK2977456T3 (en) 2006-08-15 2018-01-22 Univ Pennsylvania Compositions comprising HMW-MAA and fragments thereof for the treatment of cancer
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
PT2403935T (pt) 2009-03-04 2017-09-22 Univ Pennsylvania Composições compreendendo fatores angiogénicos e metedos para a sua utilização
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
HUE039038T2 (hu) * 2010-09-20 2018-12-28 Vakzine Projekt Man Gmbh Rekombináns mycobakterium, mint emberekben alkalmazható vakcina
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
JP6006909B2 (ja) * 2010-12-21 2016-10-12 マックス−プランク−ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー．ファウ． ワクチンとしての組み換えマイコバクテリウム
SI2656070T1 (sl) 2010-12-21 2016-05-31 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Ugotavljanje učinkovitosti živega rekombinantnega antimikobakterijskega cepljenja
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
BR102012003790A2 (pt) 2012-02-17 2014-04-22 Fundacao Butantan Cepa de mycobacterium recombinante, composição imunogênica e uso
CN104411327A (zh) 2012-03-12 2015-03-11 阿德瓦希斯公司 李斯特菌疫苗治疗以后的抑制细胞功能抑制
EP2834356A4 (en) * 2012-04-02 2015-09-02 Univ Arizona RECOMBINANT BACTERIUM FOR INDUCING A CELLULAR IMMUNE RESPONSE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine

Also Published As

Publication number Publication date
DE69836588T2 (de) 2007-04-05
DE69836588D1 (de) 2007-01-18
SI1007686T1 (sl) 2007-04-30
CY1106350T1 (el) 2011-10-12
WO1999010496A1 (en) 1999-03-04
CA2301879A1 (en) 1999-03-04
PT1007686E (pt) 2007-03-30
ATE347599T1 (de) 2006-12-15
JP4255209B2 (ja) 2009-04-15
ES2274580T3 (es) 2007-05-16
DK1007686T3 (da) 2007-04-10
CA2301879C (en) 2014-02-04
JP2001514000A (ja) 2001-09-11
US6673353B1 (en) 2004-01-06
EP1007686B1 (en) 2006-12-06
EP1007686A1 (en) 2000-06-14
EP0902086A1 (en) 1999-03-17

Similar Documents

Publication Publication Date Title
AU9435098A (en) Tuberculosis vaccine
PL1618128T3 (pl) Szczepionka przeciwko gruźlicy o ulepszonej skuteczności
DK1025211T3 (da) Hyaluronansyntasegen og anvendelser deraf
WO2001053312A8 (en) Novel nucleic acids and polypeptides
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
CA2085134A1 (en) Gdf-1
WO1996017072A3 (en) Recombinant alphavirus vectors
AU3431497A (en) DNA immunization against Chlaymdia infection
SI0757717T1 (sl) Cepivo proti papilomavirusu
EP1132479A4 (en) PROTEIN EXPRESSION VECTOR AND USE THEREOF
DE69637856D1 (en) Interleukin-19.
MX9708426A (es) Polipeptido hk2 de variante estable.
CA2121364A1 (en) Vaccines for actinobacillus pleuropneumoniae
AU1725797A (en) Parapoxviruses which contain foreign DNA, their preparation and their use in vaccines
HU9801384D0 (en) Clostridium perfringeus vaccine
WO1995034651A3 (en) Corticotropin-releasing factor2 receptors
IL90334A0 (en) Genetic transformation of b.thuringiensis,vectors used therefor,host cells transformed by the vectors and use of said cells as insecticides
CY2008005I2 (el) Εμβολιο κατα της παρωτιτιδας που περιεχει στελεχος ιου jeryl-lynn
CA2327434A1 (en) Dna immunization against chlamydia infection
IE960874L (en) Macif protein, genes coding therefor, expression vectors¹containing said genes, and transformant cells containing¹said protein
CA2148369A1 (en) Actinobacillus pleuropneumoniae outer membrane lipoprotein a and uses thereof
AU2043597A (en) Human taki dna encoding the same
GB9203821D0 (en) Improvements in or relating to malaria vaccine
WO1999015669A3 (fr) Toxine de clostridium, et procede de preparation de compositions immunogenes
WO2001070808A3 (en) Angiogenesis - associated proteins, and nucleic acids encoding the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase